Welcome to our dedicated page for Syndax Pharmaceuticals SEC filings (Ticker: SNDX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Syndax Pharmaceuticals, Inc. (NASDAQ: SNDX) SEC filings page on Stock Titan provides access to the company’s official regulatory disclosures, including current reports on Form 8-K and other documents filed with the U.S. Securities and Exchange Commission. These filings offer detail on financial results, material corporate events, and key regulatory milestones for Syndax’s oncology-focused business.
Recent Forms 8-K filed by Syndax include items on quarterly and year-to-date financial results, where the company furnishes press releases and presentations summarizing revenue from Revuforj® (revumenib) and Niktimvo™ (axatilimab-csfr), research and development spending, and operating expense trends. Other 8-K filings document significant events such as U.S. Food and Drug Administration approval of Revuforj for relapsed or refractory acute myeloid leukemia with a susceptible NPM1 mutation, as well as board-level changes.
For investors analyzing SNDX, these SEC documents complement earnings press releases and conference call materials by providing standardized, time-stamped records of the company’s disclosures. They help clarify how Syndax reports collaboration revenue from its agreement with Incyte for Niktimvo, how it describes its cash position and funding horizon, and how it characterizes the impact of regulatory approvals on its business.
On Stock Titan, Syndax filings are updated as new documents are posted to EDGAR, and AI-powered tools can assist in navigating complex language, highlighting items related to product approvals, clinical milestones, financial condition, and governance. Users can review 8-Ks for material events, and, where available, refer to 10-K and 10-Q filings for broader discussions of risk factors, pipeline programs, and the company’s description of its commercial-stage biopharmaceutical operations.
Syndax Pharmaceuticals is asking stockholders to vote at its 2026 virtual annual meeting on June 10, 2026 at 12:00 p.m. EDT. Holders of 88,595,948 common shares as of April 21, 2026 may participate online via meetnow.global/MUGAWRX.
Stockholders will elect two Class I directors (Pierre Legault and CEO Michael A. Metzger) to terms ending in 2029, cast an advisory say-on-pay vote on named executive officer compensation, and ratify Deloitte & Touche LLP as independent auditor for 2026.
The agenda also includes approval of a new 2026 Equity Incentive Plan covering 7,200,000 shares and a new 2026 Employee Stock Purchase Plan, both intended to support ongoing talent attraction, retention and alignment with long-term stockholder value.
Syndax Pharmaceuticals reported strong Q1 2026 growth but remained unprofitable. Total revenue reached $64.9 million, more than triple the $20.0 million reported a year earlier, driven by new cancer medicines Revuforj and Niktimvo.
Revuforj net product revenue was $48.9 million, up sharply as additional indications and greater physician adoption took hold. Collaboration revenue from Niktimvo contributed $15.9 million as its U.S. launch matured. Operating expenses fell modestly to $99.1 million, reflecting lower launch and milestone costs, while research and development spending remained high to fund multiple late‑stage trials.
Syndax narrowed its net loss to $42.7 million from $84.8 million a year earlier, helped by higher sales but partly offset by $11.8 million of royalty interest expense tied to its Royalty Pharma financing. Cash, cash equivalents and short‑term investments totaled $352.1 million as of March 31, 2026, supporting continued commercialization and development plans.
Syndax Pharmaceuticals reported first quarter 2026 revenue of $64.9 million, a 224% year-over-year increase driven by strong launches of Revuforj and Niktimvo. Revuforj net revenue reached $48.9 million, reflecting rapid uptake in relapsed or refractory NPM1-mutated and KMT2A-rearranged acute leukemias and growing use around stem cell transplant.
Niktimvo generated $55.1 million in net revenue at partner Incyte, producing $15.9 million of collaboration revenue for Syndax. Operating expenses declined modestly, and the net loss narrowed to $42.7 million, or $0.48 per share, compared with $84.8 million a year earlier.
The company ended the quarter with $352.1 million in cash, cash equivalents and short-term investments and 88.8 million common shares and prefunded warrants outstanding. Syndax guides to about $400 million in 2026 R&D plus SG&A (excluding $50 million non-cash stock compensation) and expects its current cash, investments, product and collaboration revenue, and interest income to support a path to profitability.
Syndax Pharmaceuticals Inc ownership disclosure: Vanguard Capital Management reports beneficial ownership of 4,457,143 shares of Common Stock, representing 5.05% of the class as of 03/31/2026. The filing states Vanguard has sole dispositive power over 4,457,143 shares and sole voting power over 634,564 shares. The report explains these holdings include securities held for Vanguard funds and managed accounts and names affiliate divisions exercising voting or dispositive power.
Syndax Pharmaceuticals Inc Schedule 13G/A shows The Vanguard Group reports 0 shares beneficially owned of Common Stock, representing 0% of the class. The filing explains an internal realignment effective January 12, 2026, under SEC Release No. 34-39538 causing certain Vanguard subsidiaries to report holdings separately.
Syndax Pharmaceuticals is a commercial-stage biopharma company focused on cancer and fibrotic diseases, now built around two FDA‑approved medicines and a broad development pipeline.
The company markets Revuforj (revumenib), a first‑in‑class oral menin inhibitor approved in the United States for relapsed or refractory acute leukemia with a KMT2A translocation and for relapsed or refractory acute myeloid leukemia with a susceptible NPM1 mutation in patients one year and older who lack satisfactory alternatives. Revuforj is being studied across the acute leukemia treatment continuum in multiple Phase 1–3 trials, including pivotal frontline combinations with venetoclax, azacitidine and intensive chemotherapy, and early programs in myelofibrosis and minimal residual disease.
Niktimvo (axatilimab‑csfr), a first‑in‑class CSF‑1R‑blocking antibody, is approved for chronic graft‑versus‑host disease after at least two prior systemic therapies in adults and pediatric patients weighing at least 40 kg. It showed a 75% overall response rate at the approved dose in the AGAVE‑201 study and is being co‑commercialized with Incyte in the United States, with Incyte holding ex‑U.S. rights. Axatilimab is in clinical development for newly diagnosed chronic GVHD and idiopathic pulmonary fibrosis.
The business is supported by multiple global license agreements for its core assets, extensive patent estates extending into the 2030s and 2040s, and a significant royalty financing with Royalty Pharma, which provided an upfront $350 million in exchange for a capped percentage of future U.S. axatilimab net sales.
Syndax Pharmaceuticals reported strong commercial growth for 2025 as it ramped launches of Revuforj and Niktimvo. Total revenue reached $68.7 million in the fourth quarter and $172.4 million for 2025, driven by Revuforj net revenue of $124.8 million and Niktimvo collaboration revenue of $42.4 million.
The company remains loss-making, with a 2025 net loss attributable to common stockholders of $285.4 million, or $3.29 per share, but narrowed its loss versus 2024. Cash, cash equivalents and short-term investments were $394.1 million as of December 31, 2025, supporting an R&D and SG&A expense outlook of about $400 million for 2026.
Management highlighted accelerating prescription trends, multiple late-stage trials for Revuforj across acute leukemia settings, and completion of enrollment in the Phase 2 IPF trial of axatilimab, with topline data expected in the fourth quarter of 2026 as it targets a path to profitability.
Syndax Pharmaceuticals Chief Executive Officer Michael A. Metzger reported a sale of common stock primarily to cover taxes. On 02/09/2026, he sold 17,159 shares of Syndax Pharmaceuticals common stock at a price of $21.028 per share.
The filing explains that this sale represents shares required to be sold to satisfy tax withholding obligations related to the vesting of restricted stock units, rather than a discretionary open-market sale of his full holdings. After this transaction, Metzger beneficially owned 491,690 shares of Syndax Pharmaceuticals common stock in direct ownership.
Syndax Pharmaceuticals Chief Financial Officer Keith A. Goldan reported a sale of common stock tied to tax withholding. On February 9, 2026, he sold 3,410 shares of Syndax common stock at $21.028 per share.
According to the filing, this sale represents shares required to be sold to cover tax withholding obligations arising from the vesting of restricted stock units, rather than a discretionary open-market sale. After this transaction, Goldan directly beneficially owns 140,429 shares of Syndax common stock.